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ABSTRACT
Introduction: More than 70 million people are
estimated to be infected with hepatitis C virus
globally. Glecaprevir/pibrentasvir is a widely
used treatment and has recently been approved
for an 8-week regimen for treatment-naı̈ve
patients with compensated cirrhosis in Europe
and the USA, who would previously have
received glecaprevir/pibrentasvir for 12 weeks.
This label update was based on the EXPEDITION-8
study, which included 343 treatment-naı̈ve
patients with compensated cirrhosis. However,
there is currently a lack of similarly large-scaleDigital Features To view digital features for this article
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real-world studies of the 8-week glecaprevir/pi-
brentasvir regimen in this population.
Methods: This summary of seven separate
smaller real-world studies aims to validate the
results seen in EXPEDITION-8 and provide an
up-to-date real-world reference for clinicians
making treatment decisions for patients with
compensated cirrhosis (Child–Pugh A) who may
benefit from a shorter-duration therapy with
glecaprevir/pibrentasvir. The newly emerging
real-world effectiveness data on treatment-naı̈ve
patients with compensated cirrhosis treated
with 8 weeks of glecaprevir/pibrentasvir help to
understand where further research is needed to
support patients with hepatitis C virus.
Results: Across all seven studies, glecaprevir/
pibrentasvir showed high effectiveness with an
average sustained virologic response rate of
98.1%, similar to that found in a clinical trial
setting (99.7%). Only one patient (0.5%) expe-
rienced virologic failure and treatment was well
tolerated.
Conclusion: Expanding the number of patients
eligible for the shortened treatment duration
will potentially increase treatment initiation
and completion, particularly in underserved
populations, contributing to the elimination of
hepatitis C virus.
Keywords: Fibrosis; Hepatitis C; Infectious
disease; Review; Therapeutics
Key Summary Points
Why carry out this study?
Short-duration, pangenotypic direct-
acting antivirals (DAA), such as
glecaprevir/pibrentasvir (G/P), are
increasingly important therapies, which
can support countries’ paths to meet the
World Health Organization’s target to
eliminate hepatitis C virus (HCV).
Following a recent label (SmPC and USPI)
update for G/P based on the EXPEDITION-
8 study, there is a lack of large-scale real-
world studies of similar magnitude (343
patients) for 8-week G/P therapy in
treatment-naı̈ve (TN) patients with
compensated cirrhosis (CC). This review
of smaller real-world studies will provide
an up-to-date reference for clinicians
making treatment decisions for patients
with CC that may benefit from a shorter-
duration therapy with G/P.
This review summarizes data from seven
independent real-world studies to
examine the effectiveness and safety of
G/P treatment in HCV-infected TN
patients with CC in clinical practice.
What was learned from the study?
G/P therapy for 8 weeks showed high
effectiveness, with numerically high
sustained virologic response rates at post-
treatment week 12 (an average of 98.1%
across cohorts), and was well tolerated.
This review can reassure providers that the
results obtained across smaller real-world
studies are collectively similar to that of
EXPEDITION-8, where 343 patients were
enrolled. This shorter treatment for TN
patients with CC may also be beneficial in
hard-to-reach populations.
INTRODUCTION
Effective pangenotypic hepatitis C virus (HCV)
treatment is available through all-oral direct-
acting antiviral (DAA) therapies [1]. However,
despite the availability of these treatments,
prevalence of HCV remains high, often due to a
lack of diagnosis and treatment [2]. In 2016, it
was reported that approximately 13% of
patients aware of their positive HCV status were
being treated [3].
If left untreated, chronic HCV infection can
lead to complications such as hepatic
4034 Adv Ther (2020) 37:4033–4042
decompensation and hepatocellular carcinoma,
ultimately leading to death [1]. Untreated HCV
infection may also lead to additional routes of
transmission, particularly in high-risk groups
[4]. The World Health Organization (WHO) has
set a target to eliminate viral hepatitis as a major
public health threat by 2030 by reducing new
hepatitis B and C infections by 90% and hep-
atitis mortality by 65% [5]. However, many
countries are not on track to meet the elimina-
tion targets by 2030 [3].
Glecaprevir/pibrentasvir (G/P) is an inter-
feron-free, ribavirin-free, fixed-dose DAA drug
combination approved for the treatment of
chronic HCV genotype (GT) 1–6 [6, 7], with
studies showing high rates of sustained viro-
logic response (SVR) and well-tolerated safety
profiles [8]. Recently, the EXPEDITION-8 trial
demonstrated the efficacy and tolerability of
G/P in 343 patients without any previous HCV
treatment (treatment naı̈ve [TN]) with com-
pensated cirrhosis (CC) receiving treatment for
8 weeks [8]. These data supported an update of
the G/P treatment label to include TN patients
with CC for the 8-week regimen for GT1–6 in
Europe [6], and the USA [7], whereas previously
only patients without cirrhosis (either treat-
ment-experienced patients with GT1, 2, 4–6 and
TN patients with GT1–6) were eligible for this
treatment duration. However, following this
recent label update, there remains a lack of
large-scale real-world data of a similar scale to
the EXPEDITION-8 trial for 8-week G/P therapy
in TN patients with CC. In lieu of a large
prospective real-world cohort, this review sum-
marizes data from seven smaller real-world
studies to provide an up-to-date reference for
clinicians making treatment decisions for
patients with CC who may benefit from a
shorter treatment duration.
Increasing the number of patients eligible for
the shorter 8-week treatment with G/P has the
potential to reach newly diagnosed TN patients
by addressing barriers in the care cascade. It
may also potentially offer additional advantages
such as improved patient uptake [9] due to
reduced treatment duration and monitoring, as
well as improved adherence in patients who use
drugs [10]. This review of data from seven sep-
arate cohort studies aims to summarize newly
emerging data on TN patients with CC
(Child–Pugh A) and HCV treated in real-world
clinical practice with 8 weeks of G/P treatment
and to further understand where additional
real-world data are needed for newly diagnosed
patients with HCV across multiple populations.
METHODS
Study Selection
A literature synthesis of PubMed, American
Association for the Study of Liver Disease Con-
gress abstracts, and National AIDS Treatment
Advocacy Project abstracts was conducted from
August 2018 to April 2020 to identify publica-
tions reporting real-world evidence of 8-week
G/P in TN patients with CC. All seven studies
were retrospective, of which three were pub-
lished or peer-reviewed published manuscripts
and four were presented at major liver meetings.
As this was a summary of published real-world
studies, no ethic committee review was
required. All studies included in this summary
were approved by local institutional review
committees, each patient also gave written
informed consent before enrollment, and the
protocol was conducted in accordance with the
Declaration of Helsinki, with the exception of
the Veterans Association study which did not
require patient informed consent because the
study was observational, the Scottish HCV
study where data were obtained from the Scot-
tish Hepatitis C Database for which opt-out
consent is in place, and the TRIO study where
TRIO Health Analytics were provided with de-
identified Health Insurance Portability and
Accountability Act-compliant patient informa-
tion approved by the Western Institutional
Review Board.
Patient Populations
We present a review of individual real-world
effectiveness data from seven separate studies of
TN patients with CC who were given G/P for
8 weeks. CC (Child–Pugh A) was defined as cir-
rhosis with no prior history of liver
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decompensation, consistent with label indi-
cated populations [6, 7]. Decompensated cir-
rhosis was defined as current or past evidence of
Child–Pugh B or C classification or clinical his-
tory of liver decompensation including ascites,
bleeding esophageal varices, or hepatic
encephalopathy, with the exception of the
German hepatitis C-registry (DHC-R) which
defined decompensated cirrhosis as at least one
of the following: Child–Pugh B or C classifica-
tion; ascites; encephalopathy; esophageal-vari-
ces grade[1, red spots, bleeding; or model for
end-stage liver disease score[ 15.
Effectiveness Analyses
Effectiveness was measured using the SVR at
post-treatment week 12 (SVR12). For the global
post-marketing observation studies (PMOS), the
core population with sufficient follow-up
(CPSFU), which included patients who com-
pleted the label-recommended regimen and the
availability of HCV ribonucleic acid (RNA) data
after post-treatment day 70, virologic failure or
discontinuation due to an adverse event with
HCV RNA\50 IU/mL at the last measurement
was used for SVR12 analysis [11]. The Scottish
HCV [12] and Italian MISTRAL [13] studies used
the intention-to-treat (ITT) population, which
included all patients. The DHC-R [14] used the
modified ITT (mITT) population, which exclu-
ded patients lost to follow-up. The Italian
NAVIGATORE [15], US TRIO Health Analytics
[16], and US Department of Veterans Affairs
(VA) [17] studies used the per-protocol (PP)
population, which included patients who com-
pleted treatment. Safety profile, in terms of
deaths and adverse events (AEs) where available,
were assessed in TN patients with CC treated
with G/P for 8 weeks.
RESULTS
Data from a total of seven studies are presented:
global PMOS [11], DHC-R [14], Scottish
HCV [12], Italian MISTRAL [13], Italian
NAVIGATORE [15], US TRIO Health Analytics
[16], and US VA [17], with additional 8-week TN
CC-specific data provided for inclusion in this
review. Baseline patient demographics and
clinical characteristics, including GT and fibro-
sis stage, are presented in Table 1.
Efficacy
SVR12 rates were high ([ 95.5%) across the
majority of real-world studies included (Fig. 1).
Safety
Of the seven studies, five (PMOS, Scottish HCV,
MISTRAL, NAVIGATORE, and VA) had available
safety data for TN patients with CC treated with
G/P for 8 weeks. Across the 135 patients inclu-
ded in these cohorts, a total of two deaths were
reported, 1/24 (4.2%) in the Scottish HCV study
and 1/85 (1.2%) in the VA study [11–13, 15, 17].
Both deaths occurred post treatment and were
not deemed DAA related.
There were substantial differences in the
methodologies of safety reporting across the
studies. However, the following safety profiles
were available at the time of publication. In the
PMOS study, 2/12 (16.7%) patients experienced
an AE and no patients experienced a serious AE
(SAE). In the Scottish HCV study, there were no
significant AEs attributed to the study drug, and
one death post treatment due to an illicit drug
overdose. In the MISTRAL and NAVIGATORE
studies there were no AEs reported. In the DHC-R
study, the safety profile was only available for
16/20 patients, with no patient experiencing an
SAE. The TRIO study was an effectiveness-only
analysis and therefore no safety data were
available. In the VA study there was one death
post treatment but before SVR testing which
was not deemed treatment related.
DISCUSSION
In general, it seems possible that the effective-
ness of HCV treatments in real-world clinical
practice may be lower than that reported in
clinical trials, potentially due to a more diverse
population [18]. It is therefore important to
examine effectiveness of HCV treatments in
real-world populations given the consequences
4036 Adv Ther (2020) 37:4033–4042
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of treatment failure. Early real-world experience
from these seven individual studies demon-
strates the effectiveness of the 8-week G/P regi-
men in TN patients with CC with 212/216
(98.1%) patients achieving SVR and only 1/216
(0.5%) experiencing virologic failure. Further
real-world studies are needed to support these
results. Across most studies, the majority of
patients were GT1, except the PMOS, MISTRAL,
and NAVIGATORE studies where the majority
of patients were GT3 (41.7%), GT2 (54.5%), and
GT2 (67.3%), respectively [11–15]. Additional
effectiveness and safety data, including
migrants, prisoners, men who have sex with
men, patients with mental health diagnoses,
patients with comorbidities, and more descrip-
tive drug use should be considered in future
studies, as well as the under-representation of
GT3, GT5, and GT6. However, patients with
other GTs have shown similar real-world results
as seen in clinical trials, providing reassurance
to the applicability of a shortened treatment
duration. Further research is also required on
the potential for drug–drug interaction in TN
patients with CC receiving 8-week G/P treat-
ment, and possibly further shortening of HCV
treatment given the high effectiveness shown.
In addition, future studies are needed to
demonstrate the value of a shorter treatment
duration within test and treat programs and
point-of-care approaches, where diagnosis and
treatment are given in a single visit [19].
The heterogenous data summarized in this
review are limited to the data available at the
time of publication of the seven separate
cohorts. Limitations arising from summarizing
data captured from seven separate cohorts
include the lack of uniform data collection and
the limited utility of pooling data due to the
different methodologies and study populations.
Another limitation of this review is the use of
mITT and CPSFU populations in some studies,
which do not include missing SVR data for
patients lost to follow-up and therefore only
present data for patients who completed follow-
up. This could potentially lead to underreported
relapses and could potentially affect the con-
clusions drawn.
The majority of the real-world SVR12 rates
presented here were similar to the results of theT
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EXPEDITION 8 registration study (PP: 99.7%
[334/335]) [8], which led to a G/P label update
to include TN patients with CC for the 8-week
regimen for GT1–6 in Europe [6] and the USA
[7]. This similar efficacy is an important finding
from this collection and review of smaller
cohorts, which can be used in lieu of a large-
scale prospective real-world study of a similar
cohort size as in EXPEDITION-8. Increasing the
number of patients with HCV who are eligible
for shorter treatment duration has the potential
to improve treatment initiation and comple-
tion, as well as reduce healthcare costs. This
more inclusive indication for the 8-week treat-
ment duration is of particular importance for
TN patients with CC, in whom only a 12-week
duration was previously possible, providing a
new option for a shorter 8-week course of
therapy to treat their HCV infection. Further-
more, the TN HCV-infected population is
growing [20], with the majority of treatment-
experienced patients successfully re-treated
with DAAs. Epidemiology estimates suggest that
as many as 98% of TN patients with HCV would
have no cirrhosis or CC and therefore could be
treated with, and are amenable to, the 8-week
regimen [21]. In the USA, TN patients without
cirrhosis and with CC represent 98% of the HCV
patient population [16]; therefore, the majority
of patients are eligible for 8-week treatment.
Although similar high SVR12 rates are observed
for the 12-week G/P regimen, patients may
prefer a shorter duration because it is more
convenient and requires less monitoring [9].
CONCLUSION
This summary of real-world data demonstrates
that 8-week G/P is effective and well tolerated in
TN patients with CC, supporting the results of
EXPEDITION-8 and providing reassurance to
Fig. 1 SVR12 rates in TN patients with CC, GT1–6a
treated with 8 weeks of G/P. aScottish HCV study
included GT1,2,4–6, US VA study included GT1–3.
bFour patients were lost to follow-up in the ITT
population. cOne confirmed reinfection with subsequent
spontaneous clearance, no virologic failure. dOne virologic
failure. eOne patient died after completing treatment but
before SVR12 testing, one patient was lost to follow-up.
fPatients missing SVR12 data were excluded from SVR12
analysis. CC compensated cirrhosis, DHC-R German
Hepatitis C-Registry, G/P glecaprevir/pibrentasvir, GT
genotype, HCV hepatitis C virus, ITT intention-to-treat,
PMOS post-marketing observational studies, SVR12 sus-
tained virologic response at week 12, TN treatment-naı̈ve,
VA Veterans Association
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clinicians treating patients with CC. Reducing
treatment duration may help to address
remaining gaps in the cascade of care, such as a
lack of treatment initiation on behalf of either
the patient or the physician and losing patients
to follow-up. It may have greater application in
underserved patients, such as prisoners and
those with unstable lifestyles/addictive sub-
stance use whose engagement with healthcare
can be challenging.
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